Obsessive-Compulsive Disorder Clinical Trial
Official title:
Electrical Stimulation of the Internal Capsule for Intractable OCD
This study will evaluate the safety and effectiveness of deep brain stimulation in treating people with severe and otherwise treatment-resistant obsessive-compulsive disorder. We also expect to determine how DBS affects brain activity in brain circuits strongly implicated in OCD, and how such effects may relate to symptom change. This treatment study therefore also permits a unique and crucial test of current neuroanatomical models of both OCD pathogenesis and mechanisms underlying the response to treatment.
Obsessive-compulsive disorder (OCD) is a chronic and debilitating illness that affects
between 2% and 3% of the adult population of the United States. People with OCD often
experience persistent unwanted thoughts and carry out ritual-like behaviors to rid
themselves of these obsessive thoughts. Additionally, OCD symptoms are usually tied with
feelings of intense anxiety and functional impairment, making it important for people with
OCD to seek effective treatment. Although there are currently many treatment options for
OCD, including psychotherapy and medications such as serotonin reuptake inhibitors, between
40% and 60%of people with OCD only partially respond, or do not respond at all, to these
treatment methods. Given the large percentage of people who do not respond to aggressive
conventional treatments, alternative options are necessary for people with
treatment-resistant OCD. Deep brain stimulation (DBS) is a procedure that involves the se of
thin wires to carry electric current to parts of the brain associated with producing OCD
symptoms. DBS has been effectively and safely used to treat movement disorders, such as
Parkinson's disease, and may be beneficial in reducing OCD symptom severity. This study will
evaluate the safety and efficacy of DBS in treating people with severe and
treatment-resistant OCD.
Study participation through follow-up will last up to 2 years. Participants will be allowed
to remain on any pre-surgical medications or behavioral therapy programs throughout the
study. Before surgery, all participants will undergo a series of initial tests and
examinations that will include psychiatric, medical, and neuropsychological histories and
examinations.
Implantation of the devices will be performed at a single session. The leads that are
inserted into the anterior limb of each internal capsule, will be implanted under local
anesthesia. On the day of the surgery, participants will have a metal frame fixed to their
heads for support during surgery, and magnetic resonance imagining (MRI) will be used to
determine the exact placement of the wires. An extension wire will pass from the scalp area
to the subclavicular region and connect each electrode to a subcutaneous implanted pulse
generator (IPG), which will be implanted under general anesthesia. After placement of the
DBS system, the patient will be admitted to the hospital for overnight observation for
possible complications. Postoperative evaluation will consist of physical and neurological
examinations, postoperative CBC, electrolyte panel, x-rays of the head, neck, and chest, a
standard shunt series to ensure the integrity of connections, and a head CT scan to monitor
for possible postoperative intracranial hemorrhage.
Surgical implantation will be followed by a three-week period with no stimulation, and then
an intensive five-day preliminary outpatient stimulation trial, followed by longer-term
outpatient stimulation. All patients will follow the same sequence of test conditions. The
initial DBS testing will be open, followed by three blocks of testing in which the patients
and investigators administering rating scales will not be informed of the stimulation
condition. These three blocks will in general be three months long, but may be longer or
shorter depending on the stability of any clinical improvement, and the possible emergence
of symptom worsening. The remainder of the the study, up to the two-year study endpoint,
will consist of a continuation phase of active open stimulation.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |